Emmanuele A. Jannini, M.D., Giacomo Ciocca, Ph.D., Erika Limoncin, Ph.D., Daniele Mollaioli, Ph.D., Stefania Di Sante, M.D., Daniele Gianfrilli, M.D., Ph.D., Francesco Lombardo, M.D., Andrea Lenzi, M.D.
Volume 104, Issue 5, Pages 1061-1073
Conventional theories and therapies for premature ejaculation (PE) are based on assumptions not always supported by evidence. This review of the current literature on the physiology of the ejaculatory control, pathogenesis of PE, and available therapies shows that PE is still far from being fully understood. However, several interesting hypotheses have been formulated, and solid, evidence-based clinical data are currently available for dapoxetine, the unique, first-line, officially approved pharmacotherapy for PE. Further growth in the field of PE will occur only when we shift from opinion-based classifications, definitions, and hypotheses to robust, noncontroversial data grounded on evidence.
Read the full text at: http://www.fertstert.org/article/S0015-0282(15)01881-6/fulltext